Related Experiment Videos
New molecular markers for bladder cancer detection
Marcus L Quek1, Kristin Sanderson, Siamak Daneshmand
1Department of Urology, Keck School of Medicine at the University of Southern California, USC/Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Los Angeles, CA 90089, USA. quekm@usc.edu
Current Opinion in Urology
|August 10, 2004
Summary
Novel molecular markers show promise for noninvasive bladder cancer detection and surveillance, potentially improving upon current methods like cystoscopy and urinary cytology. Further research into marker panels may refine bladder cancer diagnosis and management strategies.
Area of Science:
- Uro-oncology
- Molecular diagnostics
- Biomarker research
Background:
- Bladder cancer is a prevalent genitourinary malignancy requiring invasive diagnostic methods like cystoscopy.
- High recurrence rates necessitate frequent, costly surveillance.
- Current methods, including urinary cytology, lack sensitivity for detecting low-grade superficial lesions.
Purpose of the Study:
- To review novel molecular markers for noninvasive bladder cancer detection.
- To explore advancements in diagnosing urothelial neoplasia.
- To assess the potential of new markers in improving bladder cancer surveillance.
Main Methods:
- Review of recent molecular biological techniques and diagnostic approaches.
- Evaluation of urine-based markers against urinary cytology.
- Investigation of markers such as telomerase, survivin, and multitarget fluorescence in situ hybridization.
Main Results:
- New molecular markers show promising results in detecting bladder cancer compared to urinary cytology.
- Advances in understanding urothelial neoplasia pathogenesis are driving new diagnostic approaches.
- Challenges include lack of standardization and tumor heterogeneity, hindering widespread adoption.
Conclusions:
- Molecular markers like telomerase and survivin may enhance bladder cancer detection and management.
- These markers could improve sensitivity for low-grade lesions and enable early noninvasive detection of recurrence.
- While no single marker is 100% accurate, panels may significantly alter diagnostic and management policies.